Home » USA Broker Ratings » Eli Lilly and Company – Consensus Indicates Potential -2.2% Downside

Eli Lilly and Company – Consensus Indicates Potential -2.2% Downside

Eli Lilly and Company found using ticker (LLY) have now 14 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 188 and 120 calculating the mean target price we have 163.07. Now with the previous closing price of 166.75 this would indicate that there is a downside of -2.2%. There is a 50 day moving average of 155.74 and the 200 day MA is 145.64. The company has a market cap of $161,764m. Company Website: http://www.lilly.com

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext; Avidity Biosciences; Duke Clinical Research Institute for the prevention of chronic heart failure and mortality after an acute myocardial infarction; and AbCellera Biologics Inc., as well as an agreement with Junshi Biosciences to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Join us on our new LinkedIn page

Follow us on LinkedIn